A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.
Swiecicki PL, Zhao L, Belile E, Sacco AG, Chepeha DB, Dobrosotskaya I, Spector M, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey T, Worden FP.
Swiecicki PL, et al. Among authors: sacco ag.
Invest New Drugs. 2015 Dec;33(6):1248-56. doi: 10.1007/s10637-015-0293-8. Epub 2015 Oct 10.
Invest New Drugs. 2015.
PMID: 26453566
Clinical Trial.